Beyond the Science: Cost and Complexity of Personalized mRNA Vaccines
While individualized mRNA vaccines show immense promise for cancer, their economic viability and operational scaling remain massive hurdles.
By Grant Colby ·
melanoma — Lorien Times
New mRNA vaccine could reduce the recurrence and spread of skin cancer
The market’s reaction to Moderna and Merck's personalized mRNA vaccine for melanoma—a spectacular 177% surge in Moderna’s stock, according to CNBC—is pure adrenaline.
By Dana Whitfield ·
Moderna/Merck stock frenzy ignores universal rights for mRNA therapy
The sheer velocity of the stock market is always the most exhausting part of any major announcement.
By Aoife Gallagher ·
Moderna's 130% gain must prove US manufacturing for Medicare access
I’ve spent my life scoring things in payroll. I track whether a promise lands on a spreadsheet: who gets hired, at what wage, and if the work remains there five years from now.
By Ray Dombrowski ·
Tanning is getting hot again. Here’s what it really does to your skin
There are moments when the pursuit of superficial beauty seems less like personal choice and more like cultural compulsion.
By Sophie Naimi ·
World's first transmissible cancer in a freshwater fish discovered: What scientists know about this rare
You read these reports—of a transmissible melanoma in catfish in Lake Memphremagog—and you think, "Well, that's just nature doing its thing." But I’ve spent my life looking at…
By Ruth Behrens ·